Trials / Recruiting
RecruitingNCT07046559
A Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY4066708 in Healthy Participants
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 104 (estimated)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The main purpose of this study is to explore the safety and any side effects of LY4066708 in healthy participants. The study will also measure how much LY4066708 gets into the bloodstream and the central nervous system and how long it takes the body to remove it. The study will last up to 24 weeks for each participant.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY4066708 | Administered IV |
| DRUG | Placebo | Administered IV |
| DRUG | LY4066708 | Administered SC |
| DRUG | Placebo | Administered SC |
Timeline
- Start date
- 2025-05-13
- Primary completion
- 2027-09-01
- Completion
- 2027-09-01
- First posted
- 2025-07-01
- Last updated
- 2026-03-03
Locations
1 site across 1 country: United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07046559. Inclusion in this directory is not an endorsement.